1. Therapeutic Interchange as a Cost-Containment Measure

   • Louis E. Achusim

   Correspondence 06 December 2012 Pages: 347 - 351

2. The Costs of Medical Injury

   • William G. Johnson

   Guest Editorial 06 December 2012 Pages: 352 - 354

3. The Australian Guidelines for Subsidisation of Pharmaceuticals

   • Magnus Johannesson

   Leading Article 06 December 2012 Pages: 355 - 362

4. Medicaid Drug Utilisation Review Under OBRA 1990

   • Thomas R. Fulda
   • Steven L. Hass

   Leading Article 06 December 2012 Pages: 363 - 370

5. Optimising the Economic Efficiency of Drug Studies

   • Mary Ellen Kitler

   Review Article 06 December 2012 Pages: 371 - 387

6. The Costs and Benefits of Switching a Drug from Prescription-Only to Over-the-Counter Status

   • Fredrik Andersson
   • Evridiki Hatziandreu

   Review Article 06 December 2012 Pages: 388 - 396

7. Clinical and Economic Evaluation of Benzodiazepines

   • John S. Lyons
   • David B. Larson
   • Joseph Hromco

   Review Article 06 December 2012 Pages: 397 - 407

8. The Economic Impact of HA-1A (Centoxin) Against Endotoxin

   • Steven L. Barriere

   Original Research Article 06 December 2012 Pages: 408 - 413

9. Effect of Biological and Analytical Variation in Cholesterol Measurement on the Cost-Effectiveness of Cholesterol-Lowering Therapy

   • Léon L. Martens

   Original Research Article 06 December 2012 Pages: 414 - 421

10. The Australian Guidelines for Subsidisation of Pharmaceuticals

    • David A. Henry
    • Magnus Johannesson

    Correspondence 06 December 2012 Pages: 422 - 426

11. Is Alteplase (t-PA) More Cost-Effective than Streptokinase?

    • Lisa A. Sanchez

    Current Comment 06 December 2012 Pages: 427 - 428

12. Who Uses Streptokinase vs Alteplase (t-PA), and Why?

    • Lisa A. Sanchez

    Current Comment 06 December 2012 Pages: 428 - 429

13. Glossary of Terms Used in Pharmacoeconomic and Quality of Life Analyses

    OriginalPaper 06 December 2012 Pages: 430 - 432